Novel Therapeutics and Treatment Strategies for Medullary Thyroid Cancer

• Autores: Evan Walgama, Naifa Busaidy, Mark Zafereo
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 51, Nº. 2, 2022, págs. 379-389
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Medullary Thyroid Carcinoma is an aggressive thyroid cancer that requires a distinct approach to workup and management. Testing for germline mutations in the RET proto-oncogene is used to identify hereditary forms of disease. Testing for somatic RET mutations should be performed in cases of locally advanced or metastatic sporadic disease. Selpercatinib and Pralsetinib are super-selective RET inhibitors with decreased toxicity and increased efficacy compared to multitarget kinase inhibitors.